Viral Vector Expertise Target gene therapy developers seeking end-to-end viral vector CDMO services from early-stage to commercial scale, highlighting Brammer Bio as a specialist partner with established regulatory support and analytical development.

Geographic Footprint Leverage Brammer Bio’s multi-site reach (Florida Phase I/II development and Massachusetts commercial manufacturing) to offer clients scalable manufacturing continuity and risk mitigation across clinical to commercial stages.

Acquisition Tailwinds Capitalize on historical acquisition activity (Thermo Fisher, Catalent, Brammer’s integrations) to position Brammer as a proven, backed platform with access to broader networks, capabilities, and potential cross-sell opportunities with legacy customers.

Regulatory & QC Push Meet rising demand for robust quality control and regulatory support by offering enhanced QC laboratories, process development labs, and regulatory documentation assistance to streamline IND/CMC processes for gene therapies.

Strategic Partnerships Prospect collaborations with companies like Amicus Therapeutics and Sangamo by proposing joint manufacturing programs, scale-up pathways, and access to large-scale AAV manufacturing capacity to accelerate clinical timelines.